Market News

ABVC BioPharma (NASDAQ:ABVC) in Focus on ADHD Trial Update

Shares of clinical-stage biopharmaceutical company ABVC BioPharma (NASDAQ:ABVC) are in focus today after its Phase 2 part 2 study of ADHD candidate ABV-1505 enrolled a total of 30 patients.

The drug is being developed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and is anticipated to enroll a total of 100 patients in Taiwan and the U.S.

Moreover, the University of California, San Francisco (UCSF) has approved participation in this study. Part 1 of the study was conducted at UCSF as well.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More